Keyphrases
Clinical Outcomes
100%
Oxygen Demand
100%
High-flow Oxygen
100%
Immunocompromised Patients
100%
Tocilizumab
100%
Immunomodulatory Therapy
100%
Severe COVID-19
100%
Baricitinib
100%
Standard of Care
42%
In-hospital Mortality
42%
Superinfection
28%
Logistic Regression Analysis
14%
Increased Mortality
14%
Oxygen Supply
14%
Severe Disease
14%
Non-associated
14%
Associated Complications
14%
Survival Benefit
14%
Reduced Mortality
14%
Advanced Age
14%
COVID-19 Disease
14%
JAK Inhibitors
14%
Oxygen Support
14%
Multicenter Registry
14%
Omicron Variant
14%
IL-6 Inhibitor
14%
Incomplete Vaccination
14%
Nursing and Health Professions
Clinical Outcome
100%
Immunocompromised Patient
100%
Tocilizumab
100%
Baricitinib
100%
COVID-19
100%
Oxygen Consumption
100%
Health Care Quality
42%
Hospital Mortality
42%
Thromboembolism
28%
Superinfection
28%
Diseases
28%
Logistic Regression Analysis
14%
Mortality Rate
14%
Janus Kinase Inhibitor
14%
Interleukin 6
14%
Efficacy
14%
Medicine and Dentistry
Oxygen Consumption
100%
COVID-19
100%
Immunomodulation
100%
Immunocompromised Patient
100%
Tocilizumab
100%
Baricitinib
100%
Hospital Mortality
42%
Thromboembolism
28%
Superinfection
28%
Diseases
28%
Prospective Study
14%
Logistic Regression Analysis
14%
Interleukin 6
14%
Mortality Rate
14%
Omicron Coronavirus Variant
14%
Janus Kinase Inhibitor
14%
Primary Outcome
14%
Pharmacology, Toxicology and Pharmaceutical Science
Immunomodulation
100%
Immunocompromised Patient
100%
Baricitinib
100%
Tocilizumab
100%
Hospital Mortality
42%
Thromboembolism
28%
Superinfection
28%
Diseases
28%
Prospective Study
14%
Interleukin 6
14%
Mortality Rate
14%
Janus Kinase Inhibitor
14%